Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer
Public ClinicalTrials.gov record NCT01212822. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II Trial of Pre-operative Bevacizumab and FOLFOX Chemotherapy in Locally Advanced Esophageal Cancer
Study identification
- NCT ID
- NCT01212822
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Enrollment
- 20 participants
Conditions and interventions
Conditions
- Adenocarcinoma of the Esophagus
- Adenocarcinoma of the Gastroesophageal Junction
- Diffuse Adenocarcinoma of the Stomach
- Intestinal Adenocarcinoma of the Stomach
- Mixed Adenocarcinoma of the Stomach
- Squamous Cell Carcinoma of the Esophagus
- Stage IA Esophageal Cancer
- Stage IA Gastric Cancer
- Stage IB Esophageal Cancer
- Stage IB Gastric Cancer
- Stage IIA Esophageal Cancer
- Stage IIA Gastric Cancer
- Stage IIB Esophageal Cancer
- Stage IIB Gastric Cancer
- Stage IIIA Esophageal Cancer
- Stage IIIA Gastric Cancer
- Stage IIIB Esophageal Cancer
- Stage IIIB Gastric Cancer
- Stage IIIC Esophageal Cancer
- Stage IIIC Gastric Cancer
Interventions
- bevacizumab Biological
- fluorouracil Drug
- laboratory biomarker analysis Other
- leucovorin calcium Drug
- oxaliplatin Drug
- therapeutic conventional surgery Procedure
Biological · Drug · Other + 1 more
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 26, 2011
- Primary completion
- Oct 23, 2014
- Completion
- Jan 2, 2018
- Last update posted
- Sep 6, 2022
2011 – 2018
United States locations
- U.S. sites
- 3
- U.S. states
- 2
- U.S. cities
- 3
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Case Western Reserve University | Cleveland | Ohio | 44106 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111-2497 | — |
| University of Pittsburgh Cancer Institute | Pittsburgh | Pennsylvania | 15232 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01212822, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 6, 2022 · Synced May 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01212822 live on ClinicalTrials.gov.